Last update Nov. 16, 2018

C12H17N3O4S

Compatible

Safe product and/or breastfeeding is the best option.

Intravenous administration, every 6 to 8 hours.

Like other beta-lactams, it is excreted in breast milk in a clinically insignificant amount (Matsuda 1988, Ito 1988).

Its practically no oral bioavailability would make it difficult for the infant to pass through the breast milk ingested, except in preterm infants and an immediate neonatal period in which there may be increased intestinal permeability.

Medication of authorized use in infants and neonates (Merck 2016).

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora (Benyamini 2005, Ito 1993, Kafetzis 1981).

Alternatives

  • Meropenem (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C12H17N3O4S is Imipenem + Cilastatin in Molecular formula.

Is written in other languages:

C12H17N3O4S is also known as

Group

C12H17N3O4S belongs to this group or family:

Tradenames

Main tradenames from several countries containing C12H17N3O4S in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor %
Molecular weight Imi: 317. Cil: 380 daltons
Protein Binding IMi: 20. Cil: 40 %
T½ 1 hours
Theoretical Dose 0.03 - 0.28 mg/Kg/d
Relative Dose 0.05 - 0.84 %
Ped.Relat.Dose 0.03 - 0.56 %

References

  1. Benyamini L, Merlob P, Stahl B, Braunstein R, Bortnik O, Bulkowstein M, Zimmerman D, Berkovitch M. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. Ther Drug Monit. 2005 Abstract
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Ito K, Izumi K, Takagi H, Tamaya T, Hayasaki M. [Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period]. Jpn J Antibiot. 1988 Abstract
  4. Matsuda S, Suzuki M, Oh K, Ishikawa M, Soma A, Takada H, Shimizu T, Makinoda S, Fujimoto S, Chimura T, et al. [Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in the perinatal period. A study of imipenem/cilastatin sodium in the perinatal co-research group]. Jpn J Antibiot. 1988 Abstract
  5. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981 Abstract

Total visits

1,821

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM